1.Comparison of Jinzhen oral liquid and ambroxol hydrochloride and clenbuterol hydrochloride oral solution in the treatment of acute bronchitis in children: A multicenter, non-inferiority, prospective, randomized controlled trial.
Qinhua FAN ; Chongming WU ; Yawei DU ; Boyang WANG ; Yanming XIE ; Zeling ZHANG ; Wenquan SU ; Zizhuo WANG ; Changchang XU ; Xueke LI ; Ying DING ; Xinjiang AN ; Jing CHEN ; Yunying XIAO ; Rong YU ; Nan LI ; Juan WANG ; Yiqun TENG ; Hongfen LV ; Nian YANG ; Yuling WEN ; Xiaoli HUANG ; Wei PAN ; Yufeng LIU ; Xueqin XI ; Qianye ZHAO ; Changshan LIU ; Jian XU ; Haitao ZHANG ; Lie ZHUO ; Qiangquan RONG ; Yu XIA ; Qin SHEN ; Shao LI ; Junhong WANG ; Shengxian WU
Acta Pharmaceutica Sinica B 2024;14(12):5186-5200
The comparison between traditional Chinese medicine Jinzhen oral liquid (JZOL) and Western medicine in treating children with acute bronchitis (AB) showed encouraging outcomes. This trial evaluated the efficacy and safety of the JZOL for improving cough and expectoration in children with AB. 480 children were randomly assigned to take JZOL or ambroxol hydrochloride and clenbuterol hydrochloride oral solution for 7 days. The primary outcome was time-to-cough resolution. The median time-to-cough resolution in both groups was 5.0 days and the antitussive onset median time was only 1 day. This randomized controlled trial showed that JZOL was not inferior to cough suppressant and phlegm resolving western medicine in treating cough and sputum and could comprehensively treat respiratory and systemic discomfort symptoms. Combined with clinical trials, the mechanism of JZOL against AB was uncovered by network target analysis, it was found that the pathways in TRP channels like IL-1β/IL1R/TRPV1/TRPA1, NGF/TrkA/TRPV1/TRPA1, and PGE2/EP/PKA/TRPV1/TRPA1 might play important roles. Animal experiments further confirmed that inflammation and the immune regulatory effect of JZOL in the treatment of AB were of vital importance and TRP channels were the key mechanism of action.
2.Ruscogenin alleviates LPS-triggered pulmonary endothelial barrier dysfunction through targeting NMMHC IIA to modulate TLR4 signaling.
Yunhao WU ; Xiu YU ; Yuwei WANG ; Yalin HUANG ; Jiahui TANG ; Shuaishuai GONG ; Siyu JIANG ; Yuanli XIA ; Fang LI ; Boyang YU ; Yuanyuan ZHANG ; Junping KOU
Acta Pharmaceutica Sinica B 2022;12(3):1198-1212
Pulmonary endothelial barrier dysfunction is a hallmark of clinical pulmonary edema and contributes to the development of acute lung injury (ALI). Here we reported that ruscogenin (RUS), an effective steroidal sapogenin of Radix Ophiopogon japonicus, attenuated lipopolysaccharides (LPS)-induced pulmonary endothelial barrier disruption through mediating non-muscle myosin heavy chain IIA (NMMHC IIA)‒Toll-like receptor 4 (TLR4) interactions. By in vivo and in vitro experiments, we observed that RUS administration significantly ameliorated LPS-triggered pulmonary endothelial barrier dysfunction and ALI. Moreover, we identified that RUS directly targeted NMMHC IIA on its N-terminal and head domain by serial affinity chromatography, molecular docking, biolayer interferometry, and microscale thermophoresis analyses. Downregulation of endothelial NMMHC IIA expression in vivo and in vitro abolished the protective effect of RUS. It was also observed that NMMHC IIA was dissociated from TLR4 and then activating TLR4 downstream Src/vascular endothelial cadherin (VE-cadherin) signaling in pulmonary vascular endothelial cells after LPS treatment, which could be restored by RUS. Collectively, these findings provide pharmacological evidence showing that RUS attenuates LPS-induced pulmonary endothelial barrier dysfunction by inhibiting TLR4/Src/VE-cadherin pathway through targeting NMMHC IIA and mediating NMMHC IIA‒TLR4 interactions.
3.Erratum: Author correction to 'Ruscogenin alleviates LPS-triggered pulmonary endothelial barrier dysfunction through targeting NMMHC IIA to modulate TLR4 signaling' Acta Pharmaceutica Sinica B 12 (2022) 1198-1212.
Yunhao WU ; Xiu YU ; Yuwei WANG ; Yalin HUANG ; Jiahui TANG ; Shuaishuai GONG ; Siyu JIANG ; Yuanli XIA ; Fang LI ; Boyang YU ; Yuanyuan ZHANG ; Junping KOU
Acta Pharmaceutica Sinica B 2022;12(7):3198-3199
[This corrects the article DOI: 10.1016/j.apsb.2021.09.017.].
4.Survey the population distribution of ABO and Rh blood group in Huainan city
Wei WANG ; Youling SUN ; Boyang XIA
Chinese Journal of Primary Medicine and Pharmacy 2012;19(5):697-698
Objective To explore the ABO blood group and Rh blood group system antigen distribution in Huainan area.Methods To investigate the Huainan area of 24 035 voluntary blood donors of the ABO and Rh blood group system phenotype and gene frequency distribution by the population genetics of the blood type.Results In the Huainan area population,the gene frequency of ABO blood type distribution was r > P > q,the distribution of phenotype was O > A > B > AB,the distribution of RhD(-)frequency was 0.36%,and this result was consistent with the RhD(-)frequency of 0.2%~0.5% of the Han population in the country.Conclusion ABO blood group and Rh blood group were two separate systems,control their distributed rule in the Huainan region was very important to the clinical use of blood,establishment of a repository of rare blood group of RhD(-),alleviation the lack of state hospital transfusion,raising the level of clinical treatment and to the reducing the incidence of immunological transfusion reactions.

Result Analysis
Print
Save
E-mail